- Home
- LHX vs TAK Comparison
LHX vs TAK Comparison
Compare LHX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LHX | TAK |
|---|---|---|
| Founded | 1895 | 1781 |
| Country | United States | Japan |
| Employees | 45000 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2B | 59.8B |
| IPO Year | 2003 | 2007 |
Fundamental Metrics
Financial Performance| Metric | LHX | TAK |
|---|---|---|
| Price | $269.43 | $21.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 3 |
| Target Price | ★ $336.33 | $22.74 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.84% | 1.14% |
| EPS Growth | ★ 8.39 | N/A |
| EPS | ★ 9.13 | N/A |
| Revenue | ★ $6,182,000,000.00 | N/A |
| Revenue This Year | $8.16 | $4.54 |
| Revenue Next Year | $6.97 | $2.37 |
| P/E Ratio | ★ $29.87 | $41.25 |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $232.34 | $13.91 |
| 52 Week High | $379.23 | $21.73 |
Technical Indicators
Market Signals| Indicator | LHX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 70.24 |
| Support Level | $260.61 | $17.73 |
| Resistance Level | $309.59 | $21.73 |
| Average True Range (ATR) | 8.12 | 0.38 |
| MACD | 0.34 | -0.00 |
| Stochastic Oscillator | 56.14 | 87.64 |
Price Performance
Historical ComparisonAbout LHX L3Harris Technologies Inc.
In addition to its legacy software-defined radio franchise, L3Harris Technologies has, through a series of acquisitions, established franchises producing uncrewed aerial vehicles, sensors, avionics, space-based systems, missiles, and solid rocket motors. It is also adept at refitting civilian aircraft for military use, provides military and commercial training services, and maintains the US Federal Aviation Administration's communication infrastructure.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.